Dr Baretti on Mitigating Toxicities Associated With FGFR Inhibition in Cholangiocarcinoma

Marina Baretti, MD, discusses some common adverse effects associated with FGFR inhibition in patients with cholangiocarcinoma, as well as strategies to mitigate these AEs in clinical practice.

Related Keywords

Marina Baretti , ,Johns Hopkins Medicine ,Onclive Tv ,Fgfr ,Cholangiocarcinoma ,